Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 12/20 | 0.57 |
| ▸ | NPC1 | O15118 | 11/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.57 |
| ▸ | MAPT | P10636 | 4/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.48 |
| ▸ | RELA | Q04206 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | HAVCR2 | Q8TDQ0 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | DNM2 | P50570 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18038031 | 0.94 | RAB9A (0.58) | RAB9ANPC1SMN1; SMN2KMT2AMAPT | |
| SCHEMBL23258425 | 0.94 | RAB9A (0.49) | RAB9ANPC1SMN1; SMN2KMT2AMAPT | |
| SCHEMBL18037990 | 0.92 | RAB9A (0.54) | RAB9ANPC1SMN1; SMN2KMT2AMAPT | |
| SCHEMBL25858863 | 0.91 | RAB9A (0.53) | RAB9ANPC1SMN1; SMN2KMT2AMAPT | |
| SCHEMBL18038038 | 0.89 | RAB9A (0.60) | RAB9ANPC1SMN1; SMN2KMT2AMAPT | |
| SCHEMBL23258646 | 0.89 | RAB9A (0.60) | RAB9ANPC1SMN1; SMN2KMT2AMAPT | |
| SCHEMBL18038036 | 0.89 | RAB9A (0.50) | RAB9ANPC1SMN1; SMN2KMT2AMAPT | |
| SCHEMBL18038063 | 0.88 | RAB9A (0.59) | RAB9ANPC1SMN1; SMN2KMT2AMAPT | |
| SCHEMBL18038074 | 0.87 | RAB9A (0.58) | RAB9ANPC1SMN1; SMN2KMT2AMAPT | |
| SCHEMBL18038069 | 0.87 | RAB9A (0.58) | RAB9ANPC1SMN1; SMN2KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230271926-A1 | INHIBITION OF OLIG2 ACTIVITY | Curtana Pharmaceuticals, Inc. | 2023-08-31 | — | — | US | disclosed |
| US-20230271926-A1 | INHIBITION OF OLIG2 ACTIVITY | Curtana Pharmaceuticals, Inc. | 2023-08-31 | — | — | US | disclosed |
| US-11691951-B2 | Inhibition of Olig2 activity | Curtana Pharmaceuticals, Inc. (US) | 2023-07-04 | — | — | US | disclosed |
| US-11691951-B2 | Inhibition of Olig2 activity | Curtana Pharmaceuticals, Inc. (US) | 2023-07-04 | — | — | US | disclosed |
| US-20210347739-A1 | INHIBITION OF OLIG2 ACTIVITY | Curtana Pharmaceuticals, Inc. | 2021-11-11 | — | — | US | disclosed |
| US-20210114991-A1 | INHIBITION OF OLIG2 ACTIVITY | Curtana Pharmaceuticals, Inc. | 2021-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210114991-A1 | INHIBITION OF OLIG2 ACTIVITY | GLI2, ING2, GMFG | RAB9A 3638/4885NPC1 4224/4885SMN1; SMN2 111/4885 |
| US-11691951-B2 | Inhibition of Olig2 activity | GLI2, ING2, GMFG | RAB9A 3638/4885NPC1 4224/4885SMN1; SMN2 111/4885 |
| US-20210347739-A1 | INHIBITION OF OLIG2 ACTIVITY | GLI2, ING2, GMFG | RAB9A 3638/4885NPC1 4224/4885SMN1; SMN2 111/4885 |
| US-20230271926-A1 | INHIBITION OF OLIG2 ACTIVITY | GLI2, ING2, GMFG | RAB9A 3638/4885NPC1 4224/4885SMN1; SMN2 111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.